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A B S T R A C T
Purpose: To assess time trends of testicular cancer (TC) mortality in Spain for period 1985–2019 for age
groups 15–74 years old through a Bayesian age–period–cohort (APC) analysis.Methods: A Bayesian age–
drift model has been ﬁtted to describe trends. Projections for 2005–2019 have been calculated bymeans
of an autoregressive APC model. Prior precision for these parameters has been selected through
evaluation of an adaptive precision parameter and 95% credible intervals (95% CRI) have been obtained
for each model parameter. Results: A decrease of 2.41% (95% CRI: 3.65%; 1.13%) per year has been
found for TC mortality rates in age groups 15–74 during 1985–2004, whereas mortality showed a lower
annual decrease when data was restricted to age groups 15–54 (1.18%; 95% CRI: 2.60%; 0.31%).
During 2005–2019 is expected a decrease of TC mortality of 2.30% per year for men younger than 35,
whereas a leveling off for TC mortality rates is expected for men older than 35. Conclusions: A Bayesian
approach should be recommended to describe and project time trends for those diseases with low
number of cases. Through this model it has been assessed that management of TC and advances in
therapy led to decreasing trend of TC mortality during the period 1985–2004, whereas a leveling off for
these trends can be considered during 2005–2019 among men older than 35.
 2010 Elsevier Ltd. All rights reserved.
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Testicular cancer (TC) is the most common cancer among men
aged 15–44 in European population, where the lowest incidence
and mortality rates from TC are found in Eastern and Southern
European countries [1]. Based on the most updated estimates,
Spain is the Southern European country with lowest incidence (1.9
per 100,000 men-years) and mortality rates (0.1 per 100,000 men-
years), accounting for 1% of the cancers in Spanish men [1].
TC mortality had declined in the majority of European
countries, whereas incidence had risen in all 12 European
countries studied with highest increases were found in Slovenia
and Spain [2,3]. Causes of TC are largely unknown with no
satisfactory hypotheses to explain the trends, although evidence
suggests that the process of carcinogenesis could be initiated
perinatally [4] or early in life [5], perhaps even in utero [6]. TC is* Corresponding author at: Catalan Plan for Oncology, Institut Catala` d’Oncologia
– IDIBELL, Gran Via s/n, km 2,7 L’Hospitalet de Llobregat, Barcelona 08907, Spain.
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doi:10.1016/j.canep.2010.03.003also associated with cryptorchidism [7] being its etiologic fraction
around 10%. Maternal factors during pregnancy as smoking have
been also associated although need further investigation [8,9].
An increase inmortality from TCwas observed in someWestern
countries until the beginning of the 1980s followed by a decline
afterwards [2]. However, mortality rates from TC in some Eastern
andSouthernEuropeancountriesdidnotdecline,with theexception
of Italy (4% decline per annum during the period 1980–1998) [2].
However, trends in TC mortality are difﬁcult to analyze in these
studies because of the small number of deaths from this cause.
At present, only two studies analyzed TC mortality trends
speciﬁcally in Spain, although their period of analysis was
comprised between 1950 and the beginning of the 1980s. Both
studies showed a slight decrease in mortality at the end of the
study period [10,11]. The most recent analysis of TC mortality
trends in Spain has been carried out during 1994–2003, being
reported a non-statistically signiﬁcant decreasing trend [12].
A time trends study has been carried out through a Bayesian
age–period–cohort (APC) analysis, with the aim to estimate the
effects of the age and period of death and birth cohort on TC
mortality [5–13]. The Bayesian method extracts the necessary
information from the data to describe the observed trend. Thiseasing trend of testicular cancer mortality in Spain during 2005–
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achieving sensible predictions in situations when other methods
could fail, especially when the number of cases is small, as the case
of TCmortality. This Bayesian APCmodel is particularly interesting
because it allows the uncertainty associated with functions of the
parameters to be readily explored.
The aims of our study are: (i) to assess recent time trends of TC
mortality in Spain based on themost updated data available, which
refers to the period 1985–2004, and taking into account the effect
of birth cohort, age and period of death, and (ii) to estimate future
trends of TC mortality in Spain, period 2005–2019.
In this study Bayesian models have been ﬁtted using WinBUGS
[13] through the statistical package R [14,15]. WinBUGS and R-
code formodels and graphical representation of the age, period and
cohort effects are both described in Appendices A and B.
2. Materials and methods
2.1. Data and population
The National Institute of Statistics of the Spanish Government
(Instituto Nacional de Estadı´stica, INE, http://www.ine.es/) has
provided mortality data and population age distribution for the
period 1985–2004, aswell as future population for the period 2005–
2019. In Spain, throughout the period 1977–1998, the code for TC
was 186 according to the ninth revision of the International
Classiﬁcation of Diseases (ICD-9) and since 1998, the code was C62
according to the tenth revisionof the ICD (ICD-10). [16]. TCmortality
rates were age-standardized using the world standard population.
Data was arranged in four 5-year periods (1985–1989, 1990–1994,
1995–1999, 2000–2004), and twelve 5-year age groups (15–20
years to 70–74 years). These age groups and calendar periods
involved 15 (12 age groups + 4 periods 1) overlapping 10-year
cohorts due to the relation cohort = period-age [17]. The cohort
groups were deﬁned by their mid-years starting with 1915 cohort
and ﬁnishing with the cohort 1985 cohort (1910–1919,. . .,1945–
1954,. . .,1980–1989), being the central cohort thatwith central year
1950 (1945–1954). Let us deﬁneA = 12, P = 4 and C = 12 + 4 1 = 15
the number of effects for age, period and cohort, respectively.
2.2. Statistical models
In this Bayesian analysis, model parameters were assessed
through their 95% credibility intervals (95% CRI) [18–21]. Let u be
our model parameter of interest such as a certain age, period or
cohort effect being its knowledge formulated as a probability
distribution. If an interval has 95% probability under this
distribution, then this interval is called 95% credibility interval
with 95% credibility. Although it is very common to interpret
credibility intervals (CRIs) as conﬁdence intervals, the CRI
incorporates information from the prior distribution into the
estimate, while conﬁdence intervals are based solely on the data.
On the contrary, conﬁdence intervals must be interpreted as a
range in which the mean would occur 95% of the time with
repeated sampling, considering the mean to be ﬁxed with no
probability distribution [22], whereas CRI interval is the range of
values for the parameter of interest and among those, it could
include also the median and the mean. In this analysis statistical
signiﬁcance of the parameters was considered when the 95% CRI
did not include the 0 value. The procedure of modeling has been
divided into sections described below.
2.3. Estimation of the annual percent change of rates
Let la p be the observed mortality rate (age-speciﬁc) for the age
group a in the period p, where la p ¼ Yap=Nap, being Yap andNap thePlease cite this article in press as: Cle`ries R, et al. Monitoring the decr
2019 through a Bayesian approach. Cancer Epidemiology (2010), doobserved number of deaths and the person-years at risk,
respectively, in the age group a and period p. Assuming
YapPoissonðNapla pÞ the Bayesian age–drift model used to
estimate the annual percent change of increase in the number
of cases (EAPCH) [17] during 1985–2004 is
logðla pÞ ¼ ha þcð p p0Þ
logðEðYapÞÞ ¼ logðNapÞ þ ha þcð p p0Þ
haNormalð0; t2Þ
cNormalð0; t2Þ
t2 ¼ 0:001
; (1)
where ha the intercept term of the model and c the slope of the
model. This isa linearmodel in thenatural logarithmscaleof theage-
speciﬁcrates,wherep representsthecentralyearofthe5-yearperiod
and p0 the central year for the basis period which is 1987 (period
1985–1989). Therefore the EAPCH can be estimated by means of
ðec  1Þ  100 equation [17]. Non-informative Normal prior dis-
tributions [19], with mean 0 and low prior precision (inverse of the
variance) t2, have been assumed for age–drift model parameters.
2.4. Bayesian age–period–cohort modeling
Let H ¼ fa1; . . . ;a12g be the set of age effects, B ¼ fb1; . . . ;b4g
be the set of period effects and G ¼ fg1; . . . ;g15g be the set of
cohort effects. The magnitude of the rates can be described by an
APC model la p ¼ aa þ b p þ gc , with the birth cohort c derived
from period and age such that c = p  a for c in {1, 2,. . ., C} [17].
Due to this linear relation between age, period and cohort, the
non-identiﬁability of model parameters problem arise [17] when
these parameters have to be represented. We have adapted the
Holford approach in order to represent the effects [23–26]. We thus
circumvented thenon-identiﬁabilityproblemandpresentedunique
estimates for the period and cohort effects by ﬁrstly assuming a
cohort slope of zero, implying that period effect inﬂuences were
entirely responsible for the time trend. A priori evidence suggested
that the presentation of themortality trends should incorporate the
well-known beneﬁts from treatment, which should show up as
period-related effects. To represent these effects, ﬁrst we ﬁtted an
age–period (AP) model, la p ¼ aa þ b p to the observed rates,
assuming that the reference period is 1985–1989. The ﬁtted values
obtained through this AP model, Y ¼ Nap  eaaþb p , are introduced
into an only-cohort (OC) model as the offset values
Yap ¼ logðYa pÞ þ gc . Note that OC model does not include age
effects andmust not be considered an age–cohort (AC)model. In the
OCmodelwe assumed a certain reference cohort, gR, in this analysis
the cohort number 8 related with the central birth cohort of 1950.
Thenwe graphically depicted the age and period effects through the
ða1; . . . ;a12; b1; . . . ;b4Þ parameters estimated by means of the AP
model, whereas cohort effects, ðg1; . . . ;gR ¼ 0; . . . ;g15Þ, were
extracted from the OC model [23–26]. By this procedure the
standard deviations of the estimated values of the effects can be
obtained assuming that the secular trend is related to the period
effect. The resulting effects are close to those obtained with the
approachofHolford [23–26]. Theadaptationof this procedure to the
Bayesian framework in R andWinBUGS (see Appendix A) could lead
to slightly higher variability than that of the frequentist one due to
the simulation method internally implemented in WinBUGS [13].
2.5. Prior distributions for age, period and cohort effects and their
prior adaptive precision parameter
As TC is a mortality cause with low number of cases, trends
could be modeled through speciﬁc smoothing of model para-easing trend of testicular cancer mortality in Spain during 2005–
i:10.1016/j.canep.2010.03.003
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for all effects, whereas second order differences of this RW2 have
been constrained for age parameters, assuming that one second
order difference is estimated as the mean value on the previous
and subsequent second order differences [18,20]. Thus, the age
effect has been constrained to
aija j; j 6¼ iNðmai ja j ; j 6¼ i; tageÞ
ma1 ja2 ;a3 ¼ 2a2  a3
ma2 ja1 ;a3 ;a4 ¼
2a1 þ 4a3  a4
5
mai jaiþ1 ;aiþ2 ;ai1 ;ai2 ¼
4ai1 þ 4aiþ1  ai2  aiþ2
6
; 3  i  A 2
maA1 jaA ;aA2 ;aA3 ¼
2aA þ 4aA2  aA3
5
maA jaA1 ;aA2 ¼ 2aA1  aA2
tage ¼ Ks 1s2age
sageUniformð0:01;1Þ
(2)
being ai the effect of the ith age group, (1,. . .,A = 12), mai ja j ; j 6¼ i its
prior mean value, sage its prior standard deviation and tage its prior
precision (inverse of the prior variance) [19]. Prior standard
deviation of the parameters have been modeled through uniform
prior distributions on interval [0.01,1] which they are expected to
perform well unless the number of levels of the variable is
approximately below ﬁve [21]. Note that precision includes an
extra parameter denoted as Ks which allows for adapting prior
precision of these models to different diseases. This adaptive
parameter has been assumed to be the same for all effects. Period
parameters, fb1; . . . ;b4g, have been modeled through second
degree autoregressive smoothing as
b1 ¼ 0
b2Nð0; tperiodÞ
bijbi1;bi2Nðmbi jbi1 ;bi2 ;10
6tperiodÞ;3  i  P
mbi jbi1 ;bi2 ¼ 2bi1  bi2;3  i  P
tperiod ¼ Ks
1
s2period
speriodUniformð0:01;1Þ
: (3)
Note that b1 = 0 refers to the reference period, in this case the ﬁrst
period. In the same line, cohort parameters, fg1; . . . ;gR ¼
0; . . . ;g15g were modeled through
g1Nð0; tcohortÞ
g2Nð0; tcohortÞ
g ijg i1;g i2Nðmg i jg i1 ;g i2 ; tcohortÞ;3  i  R 1
gR ¼ 0
g ijg i1;g i2Nðmg i jg i1 ;g i2 ; tcohortÞ;Rþ 1  i  C
mg i jg i1 ;g i2 ¼ 2g i1  g i2
tcohort ¼ Ks
1
s2cohort
scohort Uni formð0:01;1Þ
; (4)
being R = 8 the central and reference cohort considered in our
study.Please cite this article in press as: Cle`ries R, et al. Monitoring the decr
2019 through a Bayesian approach. Cancer Epidemiology (2010), do2.6. Selecting adaptive precision
Deviance Information Criterion (DIC) has been used as Bayesian
model selection criterion [22]. DIC is the sum of the posterior
deviance and the effective number of model parameters (pD). The
lowest value of DIC indicates the best ﬁtting model with best out-
of-sample predictive power [22] and, therefore the selected one to
perform predictions. We tested DIC values for AP, AC and APC
models in ﬁve scenarios, depending on the value for Ks. For this
analysis we have evaluated Ks in ﬁve different situations, such that
Ks 2f1; 0:1; 0:01; 0:001; 0:0001g. We have denoted this para-
meter as the adaptive precision parameter. The adaptive precision
parameter selected has been used (1) in the AP and AC models for
graphic representation of rates as well as (2) for the APC model
used for projections.
2.7. Modeling projections
An APC model with RW2 for all parameters using formulation
described in Eqs. (2–4) have been ﬁtted to 1985–2004 data. The
RW on the period and cohort model parameters allows extra-
polating future values for these parameters and, therefore, the
future trends of the rates, whereas the RW on age effects allows
exponential smoothing of the rates [18–20]. In this line and due to
the relation cohort = period-age, the future number of deceased TC
cases has been predicted for 3 periods (2005–2009, 2010–2014 and
2015–2019) and, therefore, for 2 future cohorts (1985–1995,
1990–1999 and 1995–2004). The expected number of TC deceased
cases for 2005–2019 has been obtained through the Bayesian APC
model selected taking into account the value of the adaptive
parameter, Ks. The age–drift model of Eq. (1) has been also used to
estimate future EAPCH during period 2005–2019 once predictions
have been performed, using as p0 the year 2007which is the central
one for period 2005–2009.
3. Results
During 1985–2004, a total of 763 deaths (38 deaths per year)
from TC were observed in Spain. From these, 581 deceased cases
(29 deaths per year) were found in the age groups 15–54 years old.
Table 1 shows the procedure for the selection of the adaptive
precision parameter Ks. The inﬂuence of the adaptive precision
parameters can be assessed through the different DIC values. In
this analysis we have selected the value 0.001 because AP, AC and
APC models tested showed the lowest DIC values.
Fig. 1 depicts the age, period and cohort effects during the
period 1985–2004 and their 95% CRI. The age effect showed an
exponential rising before the age of 30, climbing to a crude TC
mortality rate near 5 cases per 1,000,000men-years. After this age,
there was a dramatic decrease, reaching a stabilization of rates
near the age of 40. Curvature of the cohort effect showed a decrease
on risk from the 1935 birth cohort and a stabilization near to the
1965 birth cohort with small rise for the youngest cohorts. The
period effect witnessed a continuous decrease after the initial
period of death (1985–1989, reference period).
The age–drift model enabled to estimate the EAPCH during
1985–2004. The EAPCH was 2.41% (95% CRI: 3.65%; 1.13%),
whereas TCmortality rates decreased by1.18% (95% CRI:2.60%;
0.31%) when the analysis was restricted to age groups 15–54.
However, EAPCH for men younger than 35 was not found to be
statistically signiﬁcant (EAPCH 0.97%; 95% CRI: 2.78%; +0.86%).
Fig. 2 shows age-speciﬁc projections for TC mortality rates in
Spain during 2005–2019 and their 95% CRI. Based on these
projections, a leveling off for TC mortality rates among Spanish
population would be reached among men older than 35, whereas
higher variability was observed among men younger than 35. Iteasing trend of testicular cancer mortality in Spain during 2005–
i:10.1016/j.canep.2010.03.003
Table 1
Procedure for the selection of the adaptive precision parameter using Deviance Information Criterion (DIC) and the effective number of model parameters (pD).
Ks: adaptive precision parameter Ks=1 Ks=0.1 Ks=0.01 Ks=0.001
a Ks=0.0001
Model DIC pD DIC pD DIC pD DIC pD DIC pD
Age–period 309.28 12.19 307.13 12.26 306.18 11.16 299.15 14.25 299.18 14.27
Age–period–cohort 250.21 24.12 243.98 24.16 241.98 25.01 236.45 25.35 239.41 25.52
DIC: Deviance Information Criterion. DIC =PDev+pD. PDev: posterior deviance; pD: Effective number of model parameters.
a The adaptive precision parameter selected due to DIC value is the minimum observed among models. Note the inﬂuence of the precision parameters on the predictive
performance of the models due to model with lowest DIC value best predictive performance shows.
Fig. 1. Age, period and cohort effects for testicular cancer mortality rates in Spain during the period 1985–2004.
Fig. 2. Projection of the mortality rates (per 1,000,000 men-year) by testicular cancer in Spain for the age groups 15–74 years according to period of death. Projections for
periods 2005–2009, 2010–2014, 2015–2019 (dashed line - - -) and their 95% credibility intervals (solid line —).
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Table 2
Expected number of deaths from testicular cancer in Spain for periods 2005–2009, 2010–2014, 2015–2019: age groups 15–34, 15–54, 55–74 and 15–74.
Period 15–34
(N)
35–54
(N)
55–74
(N)
15–74
(N)
1985–1989 90 60 69 219
1990–1994 112 40 40 192
1995–1999 78 60 42 180
2000–2004 99 43 30 172
Projections—period (N and 95% CRI) (N and 95% CRI) (N and 95% CRI) (N and 95% CRI)
2005–2009 66 (43; 83) 63 (46; 84) 37 (29; 43) 166 (128; 218)
2010–2014 58 (47; 91) 66 (43; 88) 39 (26; 48) 159 (102; 249)
2015–2019 51 (29; 90) 62 (42; 99) 28 (18; 57) 145 (75; 283)
EAPCH 2005–2019 (95% CRI) 2.3 (4.27; 0.31)a 0.71 (1.42; +0.18) 0.52 (1.05; +0.12) 1.12 (1.54; 0.63)a
N: number of expected death cases by testicular cancer in Spain (posterior median); 95% CRI: 95% credibility interval.
EAPCH 2005–2019: estimated annual percent change of TC mortality rates during period 2005–2019.
a 95% CRI does not include 0 value.
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cases in some age groups could affect these trends. According to
these results, Table 2 describes projections for the TC mortality in
Spain on the basis of mortality data from the period 1990–2004
and for age groups 15–34, 35–54 and 55–74. While the mean
number of TC cases decreases over time, 95% CRI are overlapped
along periods showing TC mortality leveling off. Future mortality
rates were estimated through the expected number of deaths from
TC during 2005–2019. A decreasing trend in TC mortality rates for
2005–2019 was estimated (EAPCH 1.12%; 95% CRI: 1.54%;
0.63%) mainly attributed to the signiﬁcant decreasing trend of TC
mortality rates among men younger than 35 years (EAPCH 2.3%;
95% CRI: 4.27%; 0.31%).
4. Discussion
Our study systematically assesses the effect of age, period and
birth cohort on TC in Spain showing the importance of the period
inﬂuence when all age groups were included in the analysis. A
decreasing mortality trend of 2.41% (95% CRI: 3.65%; 1.13%)
per annum was observed during 1985–2004, whereas decreasing
mortality trend for the age groups 15–54 was smaller. We have
shown amodeling framework for projections of TCmortality when
the number of cases is small. On the other hand, we presented a
Bayesian modeling approach to age–period–cohort analysis in
order to deal with those locations with low number of cases and,
therefore, small rates which could lead to computational problems
when projections are performed [18,20].
Since the mid 1970s, TC mortality has declined in several
European countries due to advances in treatment [27], and this has
translated to cohorts of men with successively lower risk of death
from this disease [2]. A recent study of incidence and mortality
from TC in 22 European countries showed that the ﬁrst
beneﬁciaries of therapy in these populations were those men
born after the 1970s [27]. Period-speciﬁc trends shown a reduction
in risk of death in Spain through periods 1953–1977 [11] and
1951–1983 [10]. Both studies showed an increase of mortality
from TC among young and middle-aged males and a decline in the
older age groups. Our study results show a decreasing trend is
expected formen younger than 35 and a leveling off for those older
than 35 for period 1985–2019. The number of TC deceased cases
decreased about 26% between 1985 and 1994. Mortality risk from
TC reaches its peak between ages 20 and 34 and drops to a
stabilization of rates near the age of 40 (age effect), as it has been
observed in previous studies in Western and Eastern European
countries [2]. The increased incidence risk of testicular cancer was
detected formen 15–44 inmost industrialized countries [2,28–32].
Spain has noted recently the most rapid inclines in TC incidencePlease cite this article in press as: Cle`ries R, et al. Monitoring the decr
2019 through a Bayesian approach. Cancer Epidemiology (2010), doamong European countries, although it has one of the lowest TC
incidence and mortality rates in Europe [1,2].
The decrease of 2.41% per annum in TC mortality rates
through the period of study in age groups 15–74 could be
attributable to the introduction of cisplatin as a therapeutic agent
for advanced germ-cell tumors [27] and best-practice tumor
management [33,34] (period effects). Down-staging due to
testicular self-examination and screening are effective methods
for an early detection of this cancer, and the introduction of various
systemic adjuvant therapies have an effect on TC survival [35,36]. A
recent study on TC survival showed little differences between
western European registries which were mainly attributable to
differing stage at diagnosis [37]. The success of (1) cisplatin-
containing chemotherapy – which has been proven to be the most
effective treatment for non-seminoma testicular cancer – in terms
of reduction inmortality and (2) an adequate patient management
are also responsible for favorable trends [12,38]. These are
reﬂected on improvements in relative survival rates (RSR) among
European TC patients diagnosed through the 1990s (5-year RSR
Europe: 93% in 1990–1994 vs. 93.8% in 1995–1998, 5-year RSR
Spain: 89.3% in 1990–1994 vs. 96.7% in 1995–1999) [39,40], being
10% higher than TC 5-year RSR during the period 1983–1985 [41].
In the graphical representation of the effects we have a priori
assumed that regular trend for TC mortality was a result of period
inﬂuences, as previously described in other studies [2]. If this
hypothesiswas erroneous, a bias in all effectsmay be incurred [17].
In agreementwith our hypothesis, this fact shows the predominant
period effect. The same conclusion could be extracted from the
sub-analysis for the age groups 15–54, although the decrease of
mortality was smaller. In this line, the analysis of Spanish Age-
Standardized TC mortality rates since 1970 shows a decreasing
trend for all age groups (data not shown and extracted from http://
www-dep.iarc.fr/: EAPC for 15–74 = 2.65%with 95% CRI:3.25%;
1.23%; EAPC for 15–54 = 1.61% with 95% CRI: 2.51%; 0.71%).
Projections by model converged to stabilization of the
decreasing trend of TC mortality rates with the exception of age
groups 15–34 years old. Several limitations should be mentioned
in relation with projections. First, projected trends were based on
small numbers of TC cases and interpretation at this particular
level – trends by age group – could be difﬁcult. Importantly, we
have evaluated that the increase or decrease of ten ormore cases in
each age group could dramatically modify the projected trends.
Second, Spanish population growth could alsomodify these trends,
with special mention to immigration effect [42]. The annual
increase of immigrants in Spain could lead to a slight rise in the
number of cases. However, the known effect of ageing in
projections [43] should not modify these results due to TC is
more frequent among 15–34 years old. Despite the increase ineasing trend of testicular cancer mortality in Spain during 2005–
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to high RSR observed among Spanish population [39].
Although themedian number of total projected cases for all age
groups decreased through period 2005–2019, 95% CRI were
overlapped in all age groups. These last results lead to conclude
that no longer decreasing trend of TCmortality is expected in Spain
in these age groups, being this ﬁnding translated into a TC
mortality leveling off in the years to come.
Our modeling framework allowed estimation of the future TC
mortality trends, projecting them into the future in the smoothest
possible way, achieving sensible predictions in a framework of
modelingwhen othermethods could fail when the number of cases
is small. We have deﬁned a predictive precision parameter, Ks to
take into account in projections. Even predictive precision
parameter has been considered as a constant of order 106 in
Bayesian age–period–cohort modeling [18,20], its impact has not
been assessed in previous Bayesian APC analysis nor in the
predictions of the burden of a cancer site with low mortality rates
as TC. We ascertained Ks performance through different scenarios
assessing the DIC impact, the criteria for selecting the APC model
which was a key part in our analysis. Note that Ks affects posterior
precision of model parameters and, therefore, projected number of
cases in a future time period. We recommend sensibility analysis
for this parameter which will allow adapting our models to other
diseases.
In conclusion, this study provides a compromise between
statistical analysis and description of mortality trends from TC in
Spain, wheremanagement of TC and advances in therapy led to the
decrease of mortality from this disease during the period 1985–Please cite this article in press as: Cle`ries R, et al. Monitoring the decr
2019 through a Bayesian approach. Cancer Epidemiology (2010), do2004. The stabilization of the falls in rates over the next 15-year
period could conﬁrm thatmortality from TC should reach a plateau
as it has been observed in some western countries [2,12]. Even if
prognosis is considered as good, a group with bad prognosis could
still remain and diagnostic delay, deﬁned as the time elapsing from
the onset of tumor symptoms to the day of diagnosis, is a way to
evaluate the rapidity of diagnosis [44]. Thus, despite the recent
favorable trend due to adequate treatment and improvements in
curability from this disease in the last decade [34,35] the recently
detected rise in incidence from TC in Spain should keep a special
surveillance for this disease in the years to come among Spanish
men.
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Appendix A. R and WinBUGS codes
A.1. Graphical representation
The WinBUGS code for the analysis is described in the following two models
A.1.1. Model AP
R. Cle`ries et al. / Cancer Epidemiology xxx (2010) xxx–xxx 7
G Model
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Please cite this article in press as: Cle`ries R, et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–
2019 through a Bayesian approach. Cancer Epidemiology (2010), doi:10.1016/j.canep.2010.03.003
A.2. Model with COHORT (only-cohort model, OC model):
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A.3. R-code to run the models through library R2WinBUGS is
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Appendix B. Model for projections
This model uses RW2 for all parameters deﬁned through Eqs. (2–4) adding a constraint for age effect:
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